BRPI0806578A8 - Promotores de lactococcus e usos dos mesmos - Google Patents

Promotores de lactococcus e usos dos mesmos

Info

Publication number
BRPI0806578A8
BRPI0806578A8 BRPI0806578A BRPI0806578A BRPI0806578A8 BR PI0806578 A8 BRPI0806578 A8 BR PI0806578A8 BR PI0806578 A BRPI0806578 A BR PI0806578A BR PI0806578 A BRPI0806578 A BR PI0806578A BR PI0806578 A8 BRPI0806578 A8 BR PI0806578A8
Authority
BR
Brazil
Prior art keywords
nucleic acids
lactococcus
promoters
proteins
relates
Prior art date
Application number
BRPI0806578A
Other languages
English (en)
Inventor
Steidler Lothar
Vandenbroucke Klaas
Neirynck Sabine
Original Assignee
Actogenix Nv
Intrexon Actobiotics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actogenix Nv, Intrexon Actobiotics N V filed Critical Actogenix Nv
Publication of BRPI0806578A2 publication Critical patent/BRPI0806578A2/pt
Publication of BRPI0806578A8 publication Critical patent/BRPI0806578A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROMOTORES DE LACTOCOCCUS E USOS DOS MESMOS. A presente invenção está no campo de biologia molecular e refere-se à engenharia recombinante e expressão de proteína. Mais em particular, a invenção refere-se a ácidos nucleicos para expressão recombinante de proteínas compreendendo sequências derivadas de Lactococcus e úteis como promotores. A invenção refere-se ainda a vetores compreendendo os ditos ácidos nucleicos e células hospedeiro transformadas com eles. A invenção também compreende o uso de células hospedeiro compreendendo os ditos ácidos nucleicos ou vetores para expressão de proteínas heterólogas ou homólogas; e também para aplicação, especialmente aplicação terapêutica, das ditas proteínas a indivíduos.
BRPI0806578A 2007-01-12 2008-01-14 Promotores de lactococcus e usos dos mesmos BRPI0806578A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07447001 2007-01-12
EP07447001.4 2007-01-12
EP07120653 2007-11-14
EP07120653.6 2007-11-14
PCT/EP2008/050352 WO2008084115A2 (en) 2007-01-12 2008-01-14 Lactococcus promoters and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0806578A2 BRPI0806578A2 (pt) 2014-05-06
BRPI0806578A8 true BRPI0806578A8 (pt) 2016-11-16

Family

ID=39609090

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806578A BRPI0806578A8 (pt) 2007-01-12 2008-01-14 Promotores de lactococcus e usos dos mesmos

Country Status (11)

Country Link
US (1) US8759088B2 (pt)
EP (2) EP2115146B1 (pt)
JP (1) JP5584470B2 (pt)
KR (1) KR101557509B1 (pt)
CN (1) CN101605900B (pt)
AU (1) AU2008204442B2 (pt)
BR (1) BRPI0806578A8 (pt)
CA (1) CA2675115C (pt)
ES (1) ES2595729T3 (pt)
RU (1) RU2495129C2 (pt)
WO (1) WO2008084115A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3181682T3 (da) 2008-09-29 2021-07-05 Intrexon Actobiotics Nv Reduceret kolonisering af mikrober på slimhinden
FR2947840B1 (fr) * 2009-07-09 2011-09-02 G T P Technology S A Sequence promotrice pour l'expression de proteines recombinantes chez lactococcus lactis
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
EP2483409B1 (en) 2009-09-29 2017-03-22 Intrexon Actobiotics NV LACTOBACILLUS glyceraldehyde-3-phosphate dehydrogenase PROMOTERS AND USES THEREOF
CN103429742A (zh) * 2010-10-15 2013-12-04 康奈尔大学 用于治疗内分泌、胃肠或自体免疫性疾病的组合物和方法
BR112013030824A8 (pt) 2011-06-01 2018-04-03 Actogenix Nv Bactéria gram-positiva, ácido necleico recombinante, composição farmacêutica e vetor
JP6329903B2 (ja) 2011-09-23 2018-05-23 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 改変されたグラム陽性菌及びその使用
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
WO2013080934A1 (ja) * 2011-11-28 2013-06-06 第一三共株式会社 ヒト遺伝子由来プロモーター
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
FR2990699B1 (fr) * 2012-05-21 2016-02-05 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le stress
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
WO2014126921A1 (en) 2013-02-12 2014-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize norovirus
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
EP2994163B1 (en) 2013-05-09 2019-08-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
EP3034610A1 (en) * 2013-08-13 2016-06-22 The Kitasato Institute Novel terpenoid compound and method for producing same
WO2015023268A1 (en) * 2013-08-13 2015-02-19 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
US10383921B2 (en) 2013-08-13 2019-08-20 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
KR102081493B1 (ko) 2014-12-23 2020-02-26 일리야 팔마 에이비 상처 치유 방법
WO2016124239A1 (en) * 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
EP3280397A4 (en) * 2015-04-06 2018-08-22 President and Fellows of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
KR20170034701A (ko) 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
GB2545395A (en) * 2015-11-27 2017-06-21 The Inst Of Food Res Engineered lactococcus lactis producing biologically active GLP-1
AU2017208153B2 (en) 2016-01-14 2021-01-28 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
AU2017252409B2 (en) 2016-04-20 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
WO2017201428A1 (en) 2016-05-19 2017-11-23 President And Fellows Of Harvard College Methods of making gels and film using curli nanofibers
AU2017319707B2 (en) * 2016-09-02 2023-11-09 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
IL265177B2 (en) 2016-09-13 2025-01-01 Intrexon Actobiotics N V A microorganism that adheres to the mucosa
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
KR101992345B1 (ko) * 2017-12-29 2019-09-27 (주)메디톡스 프로모터 폴리뉴클레오티드, 신호 폴리펩티드 및 그의 용도
KR101915949B1 (ko) * 2018-01-09 2018-11-07 주식회사 쎌바이오텍 유전자 발현 카세트 및 그를 포함하는 발현벡터
EP3863655A4 (en) * 2018-10-09 2021-12-29 Second Genome, Inc. Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
JP2023500563A (ja) 2019-09-27 2023-01-10 イントレキソン アクトビオティクス エヌヴェー デー／ベー／アー プレシゲン アクトビオ セリアック病の治療
EP4417684A4 (en) 2021-10-11 2026-03-25 Ajinomoto Kk BACTERIA MODIFIED TO EXPRESS A PROTEIN TAT HETEROLOGUE
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
CN118834876B (zh) * 2024-08-21 2025-03-21 迪辅乐生物(上海)有限公司 一种乳酸菌组成型启动子、重组载体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD297839A5 (de) 1988-08-23 1992-01-23 Dana Farber Cancer Institute,Us Alpha-untereinheit des lfa-l-leukozytadhaesionsrezeptors
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
DE69232619T2 (de) 1991-02-14 2002-09-12 The General Hospital Corp., Charlestown Intestinale kleeblatt-proteine
US6221840B1 (en) 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6190658B1 (en) * 1998-05-08 2001-02-20 Webb-Waring Institute For Biomedical Research Genetically modified manganese superoxide dismutase for treating oxidative damage
ES2214049T3 (es) 1998-10-20 2004-09-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Uso de una cepa de lactococcus productora de citoquinas para tratar colitis.
US7220418B1 (en) * 1999-07-05 2007-05-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Delivery of trefoil peptides
CN1281894A (zh) * 1999-07-23 2001-01-31 中国人民解放军第二军医大学南京军医学院 转人内皮抑素(Endostatin)基因乳酸菌的方法、产品及其应用
FR2809404B1 (fr) * 2000-05-29 2002-08-30 Rhodia Chimie Sa Bacteriocine anti-listeria
DE60140626D1 (de) * 2000-10-20 2010-01-07 Bioneer As Verfahren zur fermentativen herstellung von heterologen genprodukten in milchsäurebakterien
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
ES2266515T3 (es) * 2001-05-03 2007-03-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Cepa de lactococcus con autocontencion.
EP1529114A1 (en) * 2002-08-09 2005-05-11 Chr. Hansen A/S Process for preparing peptides with anti-hypertensive properties
WO2006057289A1 (ja) * 2004-11-24 2006-06-01 Anaeropharma Science Inc. 新規シャトルベクター
KR100620092B1 (ko) 2004-12-16 2006-09-08 씨제이 주식회사 코리네박테리움 속 세포로부터 유래된 신규한 프로모터서열, 그를 포함하는 발현 카세트 및 벡터, 상기 벡터를포함하는 숙주 세포 및 그를 이용하여 유전자를 발현하는방법
DE102004061846A1 (de) 2004-12-22 2006-07-13 Basf Ag Mehrfachpromotoren
US7495092B2 (en) * 2005-01-14 2009-02-24 North Carolina State University Compositions comprising promoter sequences and methods of use

Also Published As

Publication number Publication date
RU2495129C2 (ru) 2013-10-10
CN101605900B (zh) 2014-04-23
BRPI0806578A2 (pt) 2014-05-06
AU2008204442B2 (en) 2013-03-14
AU2008204442A1 (en) 2008-07-17
RU2009130728A (ru) 2011-02-20
KR20090112650A (ko) 2009-10-28
US8759088B2 (en) 2014-06-24
CA2675115A1 (en) 2008-07-17
JP2010515445A (ja) 2010-05-13
EP3124614A2 (en) 2017-02-01
ES2595729T3 (es) 2017-01-03
US20100080774A1 (en) 2010-04-01
EP2115146B1 (en) 2016-07-06
CA2675115C (en) 2014-12-09
CN101605900A (zh) 2009-12-16
EP3124614A3 (en) 2017-04-05
JP5584470B2 (ja) 2014-09-03
KR101557509B1 (ko) 2015-10-06
EP3124614B1 (en) 2022-06-08
EP2115146A2 (en) 2009-11-11
WO2008084115A3 (en) 2009-04-09
WO2008084115A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
BRPI0806578A8 (pt) Promotores de lactococcus e usos dos mesmos
Morris et al. The host response to naturally-derived extracellular matrix biomaterials
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112012019881A2 (pt) proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
BR112014019901A8 (pt) Proteínas de fator viii recombinante
MX2016008551A (es) Moleculas artificiales de acido nucleico.
MX339126B (es) Composiciones de dominio de fibronectina estabilizadas, metodos y usos.
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
NZ609903A (en) Expression vector for high level expression of recombinant proteins
BR112016023304A2 (pt) célula hospedeira recombinante engendrada para superexpressar proteínas auxiliares
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INTREXON ACTOBIOTICS N.V. (BE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: INTREXON ACTOBIOTICS N.V. (BE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.